Fulvestrant: beside an established treatment under test
54 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingNCT07748208Phase 2Report a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3Report a problem
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingNCT07619066Phase 2Report a problem
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingNCT07405801Phase 2Report a problem
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingNCT07368998Phase 2Report a problem
- Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.RecruitingNCT07227233Phase 2Report a problem
- An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyRecruitingNCT07117630Phase 2Report a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1Report a problem
- Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibitorsNot yet recruitingNCT06929325Phase 3Report a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicableReport a problem
- Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingNCT06607757Phase 2Report a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingNCT06135714Phase 3Report a problem
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2Report a problem
- Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentCompletedNCT05631795Phase 4Results postedReport a problem
- Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)TerminatedNCT05554354Phase 2Results postedReport a problem
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingNCT05169567Phase 3Results postedReport a problem
- Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedNCT04862143Phase 2Results postedReport a problem
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results postedReport a problem
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingNCT03939897Phase 1Results postedReport a problem
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedNCT03691493Phase 2Results postedReport a problem
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedNCT03620643Phase 2Results postedReport a problem
- A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyTerminatedNCT03584009Phase 2Results postedReport a problem
- Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results postedReport a problem
- Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast CancerActive, not recruitingNCT02955394Phase 2Results postedReport a problem
- Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedNCT02536742Phase 2Results postedReport a problem
- S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerTerminatedNCT02137837Phase 3Results postedReport a problem
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AICompletedNCT01797120Phase 2Results postedReport a problem
- Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerCompletedNCT01142401Phase 2Results postedReport a problem
- Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase InhibitorCompletedNCT00754325Phase 2Results postedReport a problem
- Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal TherapyTerminatedNCT00570258Phase 2Results postedReport a problem
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingNCT06764186Phase 3Report a problem
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingNCT06635447Phase 3Report a problem
- Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Active, not recruitingNCT06506955Phase 2/3Report a problem
- Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)Active, not recruitingNCT06494150Phase 2Report a problem
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active, not recruitingNCT06428396Phase 2Report a problem
- Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)TerminatedNCT06408168Phase 2Report a problem
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedNCT05625087Phase 2Report a problem
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2Report a problem
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingNCT05038735Phase 3Report a problem
- Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerActive, not recruitingNCT04762979Phase 2Report a problem
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingNCT04556773Phase 1Report a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04544189Phase 2Report a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04524000Phase 2Report a problem
- Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyStatus unknownNCT04318223Phase 2Report a problem
- WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorCompletedNCT03854903Phase 1Report a problem
- Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantCompletedNCT03447132Phase 3Report a problem
- Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnNCT03377101Phase 2Report a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast CancerCompletedNCT02958852Phase 2Report a problem
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorActive, not recruitingNCT02738866Phase 2Report a problem
- Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerStatus unknownNCT02690480Phase 2Report a problem
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2Report a problem
- Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast CancerStatus unknownNCT02530411Phase 2Report a problem
- Overcoming Endocrine Resistance in Metastatic Breast CancerStatus unknownNCT02394496Phase 3Report a problem
- Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyStatus unknownNCT00688194Phase 3Report a problem